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LAM: Linear atrophoderma of MoulinINTRODUCTION
Linear atrophoderma of Moulin (LAM) is a rare
and distinct clinical entity characterized by acquired
unilateral, hyperpigmented, and atrophic bandlike
skin lesions following the lines of Blaschko. We
report a rare and interesting case of LAM.
CASE REPORT
A 22-year-old Malay woman presented with an
11-year history of asymptomatic, unilateral brown
patches affecting the right arm, right side of the
trunk, and right leg. There were no prior skin lesions
or inflammation. There was no significant medical or
family history.
Physical examination found linear hyperpigment-
ed atrophic patches on the right arm, right trunk
extending down to the right buttock, right thigh, and
right leg following Blaschko’s lines involving both
anterior and posterior aspects (Fig 1, A). The skin
was slightly atrophic on palpation. No signs of
induration or inflammation were noted (Fig 1, B).
Laboratory investigations including full blood
count, erythrocyte sedimentation rate, renal profile,
liver function test, antinuclear antibodies, double-
stranded antinuclear DNA antibodies, antieSCL-70
antibody, anti-SSA(Ro), anti-SSB(La), antieJo-1, and
anti-RNP antibodies were all negative or within the
normal range.
The first skin biopsy from a hyperpigmented
patch over the right arm found mild upper dermal
perivascular lymphocytic infiltrate. No dermal
sclerosis was seen. Skin biopsy was repeated from
normal skin (Fig 2, A) and from the hyperpigmented
patch (Fig 2, B) on the right arm. Histopathologic
examination of the affected skin found a mild
upper dermal perivascular lymphocytic infiltration.
When compared with the adjacent normal skin, the
dermal thickness was reduced and the dermal
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The diagnosis of LAM was made. Our patient was
treated with betamethasone, 0.1% cream twice a day
for 6 months, with no improvement. She then tried
hydroquinone 4% cream for 2 years of which also
failed to improve the hyperpigmentation.
DISCUSSION
Moulin et al1 first described LAM in 1992, of which
only 5 cases were observed over a 17-year period.
Baumann et al2 reported on a further patient with
similar features and proposed the name linear
atrophoderma of Moulin.2
The diagnostic criteria for LAM3 include
1. Onset during childhood or adolescence
2. Development of hyperpigmented, slightly atro-
phic, unilateral lesions following Blaschko lines
on the trunk or limbs
3. Absence of preceding inflammation and absence
of subsequent induration or scleroderma
4. Stable, nonprogressive clinical course without a
pattern of remission
5. Histologic findings showing hyperpigmentation
of the basal epidermis and a normal dermis with
unaltered connective tissue and elastic fibers
Although different from the original report of
Moulin et al,1 the most common histologic finding is
a perivascular lymphocytic inflammatory infiltrate in
the superficial dermis combined with abnormal
collagen fibers.32352-5126
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Fig 1. A, Linear hyperpigmented atrophic patches on the right upper inner arm, right side of
the upper chest, right thigh and right leg following Blaschko’s lines. B, Close-up view of the
atrophic patches on right thigh.
Fig 2. A, Histopathology of the normal skin. B, Histopathologic examination of the affected
skin found reduced dermal thickness with more compact dermal collagen and mild upper
dermal perivascular lymphocytic infiltration. (Hematoxylin-eosin stain; original magnification:
340.)
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reported cases were so far sporadic. Dermatoses
that follow Blaschko’s lines are thought to be caused
by a somatic mutation that takes place early in
embryogenesis, resulting in a genotypic and pheno-
typic mosaicism. Danarti et al4 postulated that LAM
may reflect the action of an autosomal lethal gene
surviving by mosaicism. A postzygotic mutational
event may lead to loss of the corresponding wild-
type allele at the atrophoderma locus, and this gives
rise to a homozygous cell clone which becomes
manifested along the lines of Blaschko later in life.The differential diagnosis of LAM includes
congenital dermopathy following Blaschko lines
such as linear and whorled nevoid hypermelanosis,
incontinentia pigmenti, lichen striatus, and
epidermal nevi. LAM should also be differentiated
from atrophoderma of Pasini and Pierini, which also
presents with similar configuration, atrophy, and
hyperpigmentation but does not follow Blaschko
lines. Atrophoderma of Pasini and Pierini is
considered an abortive variant of morphea. In our
patient, the initial clinical diagnosis was linear
morphea. However, the clinical presentation,
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scleroderma and absence of dermal sclerosis on
histopathologic examination, led to a diagnosis of
LAM. It is important to differentiate LAM from linear
morphea, as the prognosis is different. The prognosis
of LAM is favorable, as there are no associated
complications.
There is no effective treatment for LAM. Topical
corticosteroids and heparin2 were not helpful. High
dose penicillin5 and potassium aminobenzoate6
were noted to be ineffective as well. A partial
response to topical calcipotriol was reported.7 A
case of LAM successfully treated with methotrexate
20 mg/wk for 6 months with an improvement of
pigmentation and atrophy was reported.8 The
authors suggested that LAM, atrophoderma of
Pasini and Pierini, and linear scleroderma may be a
spectrum of a common disease entity in view of the
response to methotrexate, which is an effective
therapeutic option for morphea. However, some
cases of LAM do not respond to potent topical
steroids and topical calcipotriol, which are the
first-line treatment for morphea.
Since the original description, much debate has
occurred regarding whether atrophoderma of Pasini
and Pierini is a distinct entity or an abortive,
nonindurated variant of morphea. Subsequent
reports of the co-occurrence of morphea and
occasionally lichen sclerosus with atrophoderma of
Pasini and Pierini suggest a close relationship
between atrophoderma of Pasini and Pierini and
morphea. However, Yokoyama et al9 reported that
skin glycosaminoglycans extracted from atropho-
derma of Pasini and Pierini lesions are different from
those in typical morphea lesions.
It remains controversial whether LAM is a distinct
entity or on a spectrum of a common disease
entity with atrophoderma of Pasini and Pierini andlinear scleroderma. Although some similarities
exist between these 3 conditions, there are also
differences in the age of onset, distribution,
histology, origin, development, and prognosis of
the lesions.
This case highlights the importance of recog-
nizing the clinical presentation of this disease with
atrophic hyperpigmented patches along Blaschko
lines. When atrophoderma is suspected, skin
biopsies should be taken from both normal skin
and lesional skin, as atrophoderma often shows very
subtle features.
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